Premium
Extravasation of an antibody‐drug conjugate: A case report of epidermal necrosis after trastuzumab‐emtansine extravasation
Author(s) -
Sallevelt Bastiaan T. G. M.,
Teunis Teun,
Agterof Mariette J.,
Broek Marcel P. H.
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13148
Subject(s) - trastuzumab emtansine , extravasation , medicine , toxicity , trastuzumab , dermatology , pathology , breast cancer , cancer
What is known and objective Trastuzumab‐emtansine is an antibody‐drug conjugate developed to decrease off‐target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate. Case summary We report on a 51‐year‐old woman who developed epidermal necrosis after extravasation of trastuzumab‐emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation. What is new and conclusion We describe the course of a case of severe toxicity following trastuzumab‐emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.